Burning Rock Biotech (BNR) Non-Current Debt (2019 - 2026)

Burning Rock Biotech (BNR) posted quarterly Non-Current Debt of $246000.0 for Q1 2026, up 2.63% quarter-over-quarter from $239687.4 in Q4 2025.

Burning Rock Biotech (BNR) Non-Current Debt (2019 - 2026) Analysis & Trends

Burning Rock Biotech's Non-Current Debt history runs 4 years deep, the most recent figure standing at $246000.0 for Q1 2026.

In Q1 2026, Non-Current Debt changed N/A year-over-year to $246000.0; the TTM figure through Mar 2026 stood at $246000.0 (changed N/A YoY), while the FY2025 annual figure was $243000.0, changed N/A from the prior year.
Non-Current Debt for Q1 2026 stood at $246000.0, up from $239687.4 in the prior quarter.
The five-year high for Non-Current Debt was $253000.0 in Q3 2025, with the low at $239687.4 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Thermo Fisher Scientific	213.40 Bn	209.33 Bn	8.34 Bn	42.28 Bn
2	Danaher	139.94 Bn	135.59 Bn	3.61 Bn	25.15 Bn
3	Idexx Laboratories	46.03 Bn	45.83 Bn	779.09 Mn	299.87 Mn
4	Agilent Technologies	39.69 Bn	37.88 Bn	990.00 Mn	3.05 Bn
5	Iqvia Holdings	39.32 Bn	37.24 Bn	1.44 Bn	13.71 Bn
6	Natera	38.47 Bn	37.37 Bn	696.04 Mn	-
7	Illumina	29.98 Bn	28.82 Bn	770.00 Mn	1.49 Bn
8	Mettler Toledo International	28.57 Bn	28.52 Bn	650.22 Mn	2.04 Bn
9	Quest Diagnostics	26.21 Bn	25.58 Bn	1.03 Bn	5.64 Bn
10	Burning Rock Biotech	781.17 Mn	711.04 Mn	11.31 Mn	246,000.00

Download Data